The 4 bullish analyst ratings for Oncolytics Biotech indicate a positive outlook for the stock. The average price target of $11.0, which has increased by 83.33% over the past month, suggests a significant potential upside from the current price of $1.75. This information is important for investors as it shows that analysts have a positive view on the stock's future performance.